Oppenheimer Starts Collegium Pharmaceutical (COLL) at Outperform
Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Outperform rating and a price target of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

